Your browser doesn't support javascript.
loading
Global Trial Representation and Availability of Tyrosine Kinase Inhibitors for Treatment of Chronic Myeloid Leukemia.
Casey, Mycal; Odhiambo, Lorriane; Aggarwal, Nidhi; Shoukier, Mahran; Islam, K M; Cortes, Jorge.
Afiliación
  • Casey M; Division of Hematology-Oncology, MedStar Georgetown University Hospital, Washington, DC 20007, USA.
  • Odhiambo L; Department of Biostatistics, Data Science and Epidemiology, Augusta University, Augusta, GA 30912, USA.
  • Aggarwal N; Department of Medicine, Medstar Georgetown University Hospital, Washington, DC 20007, USA.
  • Shoukier M; Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
  • Islam KM; Department of Biostatistics, Data Science and Epidemiology, Augusta University, Augusta, GA 30912, USA.
  • Cortes J; Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Cancers (Basel) ; 16(16)2024 Aug 14.
Article en En | MEDLINE | ID: mdl-39199609
ABSTRACT

Background:

Evaluating clinical trial representation for countries with different socio-demographic index (SDI) and tyrosine kinase inhibitor (TKI) availability for chronic myeloid leukemia (CML).

Methods:

CML incidence rates (IRs) and disability-adjusted life years (DALYs) (1999-2019) from the Institute of Health Metrics and Evaluation were analyzed. Trials investigating TKI use in CML were obtained from ClinicalTrials.gov. Site data for eligible trials (N = 30) and DALYs were analyzed. TKI approvals, DALYs, and IRs were summarized by SDI.

Results:

North America (NA) had significant decreases in annual percent change (APC) in DALYs and incidence rates from 1999 to 2004. IRs were highest in Europe and Central Asia (ECA) and NA, while DALYs were highest in South Asia (SAsia) and Sub-Saharan Africa (SSA). Countries in the high-SDI quintile were likely to have lower DALYs than lower-SDI quintiles. Differences in regional DALYs vs. sites in TKI trials were significant for SAsia, SSA, and ECA. High-SDI countries were included in all 30 trials, and TKI approvals were prominent in high-SDI (142) vs. low-SDI (14) countries.

Conclusions:

The inclusion of disproportionately affected countries during the design of and recruitment into clinical trials should occur, as should TKI availability. The lack of representation demonstrates healthcare disparities.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza